{
  "id": 16156646,
  "title": "Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines",
  "url": "https://urgent.news/2026/10/23/galdermas-relfydesstm-relabotulinumtoxina-receives-approval-in-china",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-23T05:00:16.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/galdermas-relfydess-relabotulinumtoxina-receives-approval-in-china-for-frown-lines"
  },
  "original_language": "en",
  "account": null,
  "summary": "The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2 The approval is based on phase III results from a local clinical trial conducted in China as well as global READY clinical […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}